Thomas Patrick Kelly is CFO at Xenon Pharmaceuticals Inc. (XENE). They have made 1 open-market trade across 1 company since 2026, most recently 2026-10-15.
CIK 1582313
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $560K since 2026, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| XENE | 22,500 | $754K |
Shares reported on the most recent Form 4, priced at the 2026-10-16 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XENE | BUY | 2026-09-30 | 2026-10-01 | $37.32 | $560K | -11.2% | — | — |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.